Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients

John C. Reneau, Dennis Asante, Holly van Houten, Lindsey R. Sangaralingham, Francis K. Buadi, Amir Lerman, Joerg Herrmann

Research output: Contribution to journalLetter

10 Scopus citations
Original languageEnglish (US)
Pages (from-to)E15-E17
JournalAmerican Journal of Hematology
Issue number2
StatePublished - Feb 1 2017

ASJC Scopus subject areas

  • Hematology

Cite this